Disease/Infection News

RSS

Gilead, Mylan expand license deal for HIV/AIDS medicines

Mylan Inc. today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan's Matrix Laboratories Limited.

12 Jul 2011

Rapid method can predict immune responses against flu vaccines

Researchers at the Emory Vaccine Center have developed a method for predicting whether someone will produce high levels of antibodies against a flu shot a few days after vaccination.

12 Jul 2011

HIV patients with mental illness can benefit from APRN care management

In a four-year study, researchers at the University of Pennsylvania have found that assigning adults with serious mental health illness who are HIV positive to the care of advanced practice nurses (APRN) to help navigate the health care system and maintain adherence to drug regimens reduced depression and improved their overall physical health, indicating that healthcare policy should be revamped to provide this support.

12 Jul 2011

UNC receives $32 million federal grant to eradicate HIV infection

Researchers at the University of North Carolina at Chapel Hill have been awarded a $32 million, five-year federal grant to develop ways to cure people with HIV by purging the virus hiding in the immune systems of patients taking antiretroviral therapy.

12 Jul 2011

Haiti passed up cholera vaccine offer, Crucell CEO says

Ronald Brus, CEO of the Dutch vaccine maker Crucell, said Haiti did not accept an offer of tens of thousands of cholera vaccine doses late last year, the Financial Times reports.

12 Jul 2011

Type-3 polio virus case in Pakistan raises concerns of disease spreading, WHO says

Pakistan has reported the first case of the type-3 wild polio virus in six months, raising concerns that the disease may spread to other parts of Asia and beyond, the WHO said on Thursday, Bloomberg/San Francisco Chronicle reports.

12 Jul 2011

New research strategy for eradicating HIV from the body

An international team led by researchers from the University of California, San Francisco and the nonprofit Vaccine and Gene Therapy Institute of Port St. Lucie, Fla., has received a major grant from the National Institutes of Health to develop a strategy to eradicate HIV from the body.

12 Jul 2011

Merck researchers to participate in two new collaborative efforts to study HIV latency

Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.

12 Jul 2011

Gilead announces expansion of global access program for HIV medications

Gilead Sciences, Inc. announced today an expansion of its global access program in an effort to provide accelerated access to Gilead medicines for the treatment of HIV/AIDS.

12 Jul 2011

Hutchinson Center receives $20M NIH grant to eradicate HIV infection

Whether a stem cell transplant using an HIV-infected person's own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced today by the National Institutes of Health to Fred Hutchinson Cancer Research Center.

12 Jul 2011

Scientists to receive prestigious awards for innovative HIV research at IAS 2011

The International AIDS Society (IAS) announced today the six winners of three prestigious scientific awards, to be presented at plenary sessions during the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention to be held in Rome July 17-20, 2011.

12 Jul 2011

Federal funds may help Gladstone to solve problem of HIV latency

The Gladstone Institutes will receive funds totaling $5.6 million over five years as part of the first-ever major funding initiative focusing on HIV eradication.

12 Jul 2011

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed enrollment of the first 40 subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

12 Jul 2011

New ‘world-first’ Malaria vaccine in the pipeline

Australian researchers have potentially created a ‘world-first’ malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.

12 Jul 2011

Drug resistant gonorrhea discovered

Japanese scientists have found a superbug strain of gonorrhea that’s resistant to all available antibiotics. This can pose a threat to public health worldwide, infectious disease experts say.

11 Jul 2011

NIAID awards $14 million a year for new HIV research

Three research teams focused on developing strategies that could help to rid the body of HIV are receiving grants totaling more than $14 million a year, for up to five years, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announced today.

11 Jul 2011

New gonorrhea strain resistant to all antibiotics isolated in Japanese woman

A new strain of the sexually transmitted disease gonorrhea that is resistant to all known antibiotic treatments has been isolated from a female sex worker in Japan, according to Magnus Unemo of the Swedish Reference Laboratory for Pathogenic Neisseria, Reuters reports. Unemo is set to present his findings at a conference of the International Society for Sexually Transmitted Disease Research in Quebec on Monday.

11 Jul 2011

Microneedle patches may target dentritic cells more efficiently and induce immunity against HIV

Applying a vaccine patch to the skin with thousands of tiny micro-needles could help boost the body's immune response and prevent the spread of life-threatening infections like HIV and TB, a major Cardiff University study aims to uncover.

11 Jul 2011

RyMed's InVision-Plus Intraluminal Protection System effective against catheter-related bloodstream infections

Denise Macklin, BSN, RNC, representing the research team of Dr. Cynthia C. Chernecky Ph.D., RN, AOCN, FAAN, Dr. Jennifer Waller, Ph.D., both from Georgia Health Sciences University; and Dr. William Jarvis M.D., Jason & Jarvis Associates, exhibited a poster at the recent APIC 2011 (Association for Professionals in Infection Control and Epidemiology) conference in Baltimore, titled "Clinical Comparisons of Split Septum, Positive and Negative Mechanical Valve Intravenous Connectors to an Intraluminal Protection Connector on Infection Rates."

11 Jul 2011

Fibrin key to protection during gram-negative sepsis

New research from the Trudeau Institute may help to explain why anticoagulant therapies have largely failed to extend the lives of patients with sepsis. The study was led by Deyan Luo, a postdoctoral fellow in Stephen Smiley's laboratory. It shows that fibrin, a key product of the blood clotting process, is critical for host defense against Yersinia enterocolitica, a gram-negative bacterium that causes sepsis in humans and experimental mice.

11 Jul 2011